Paula Soteropoulos, a member of the board at Dianthus Therapeutics, Inc. (NASDAQ:DNTH), sold 599 shares of the company's common stock on March 31, 2026. The shares were sold at $80.11 each, producing total proceeds of $47,985. On the same date she exercised stock options to purchase 599 shares at $8.44 per share, for an aggregate exercise amount of $5,055.
The option exercise and share sale relate to an equity plan with a vesting schedule that placed 25% of the shares into Soteropoulos' ownership on April 6, 2023, with the remaining portion vesting monthly over the subsequent three years. The sale itself was executed under a pre-arranged Rule 10b5-1 trading plan that the director adopted on December 23, 2025.
Since the sale, Dianthus Therapeutics' stock has advanced to $84.54, trading near its InvestingPro-tracked 52-week high of $88.49. Over the past year the share price has appreciated by 402%. An analysis noted in market coverage indicates the stock appears overvalued relative to its Fair Value.
Concurrent with these insider transactions, Dianthus completed a public offering that raised approximately $719 million in gross proceeds. The offering involved the sale of 8,470,989 shares at $81.00 per share, a total that includes shares issued upon exercise of underwriters’ options. The company also issued pre-funded warrants exercisable for up to 402,468 shares, with an exercise price of $0.001 per share.
Market analysts have responded to recent corporate and clinical developments. William Blair assigned an Outperform rating to the company after an FDA update altered safety screening requirements for the company's claseprubart clinical trials, a change that the firm described as positive. William Blair also reiterated its Outperform rating following interim results from the CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy, citing competitive efficacy and safety outcomes. Separately, Wells Fargo maintained an Overweight rating with a price target of $135.00.
These events - an insider sale executed under a Rule 10b5-1 plan, the exercise of options, a sizable equity raise through a public offering, and recent analyst coverage tied to regulatory and trial updates - together frame the current market context for Dianthus Therapeutics.